ESMO

ESMO 2023: Highlights on belzutifan in previously treated advanced clear cell RCC: The LITESPARK-005 study

By ONA Editor October 23, 2023 No Comments

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

About Author

Related Posts

Pivotal study supports belzutifan approval for patients with advanced kidney cancer

Researchers map the effects of all potential changes in key cancer gene

ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus

Leave A Reply Cancel Reply